AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 4
Description: Cereal products based on rye, barley, wheat, oat, and corn
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal product 5
Description: Cereal products based on rye, barley, wheat, oat, and corn
Study NCT03423381 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: A cereal based product with low concentrations of df
Study NCT03537937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate SpO2 Target
Description: SpO2 target 94% (range 92-96%)
Study NCT03537937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher SpO2 Target
Description: SpO2 target 98% (range 96-100%)
Study NCT01620801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV8-hFIX19
Description: One-time IV vector administration.
Study NCT03038516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
Study NCT04458974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour.
Study NCT04458974 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: The intervention consists in two-weeks treatment, 10 consecutive sessions of tDCS ( Monday to Friday) applied concurrently to neuropsychological rehabilitation.~The tDCS Multisite StratStim® 8-channel device (Neuroelectrics) will be used for tDCS stimulation. The duration of the stimulation will be 20 minutes at 2 mA. The tDCS will be applied with the cathode positioned in P3 (following the international 10/20 EEG system), and the return electrodes will be placed in C3, CP5, CP1, Pz, PO3, PO7, P7.~The sessions will last 1 hour.
Study NCT04458974 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).
Study NCT04458974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).
Study NCT04458974 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological rehabilitation
Description: The neuropsychological rehabilitation protocol has been designed for the recovery of neglect symptomatology. Each session will consist on the performance of different cognitive stimulation tasks aimed at improving attention and visoperceptive abilities. The tasks will be applied through the NeuronUp neurorehabilitation platform in order to achieve maximum homogeneity and objectivity across patients.~The neuropsychological rehabilitation will last 30min (in 1h intervention session).
Study NCT03038516 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
Study NCT00721357 — intervention group
Intervention type: BEHAVIORAL
Intervention: Treadmill walking
Description: Subjects will perform treadmill walking at a self-selected velocity
Study NCT00721357 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance spectroscopy
Description: Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
Study NCT02507050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: To start Ivabradine 6 weeks prior to PCI.
Study NCT01002040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arepanrix
Description: Group A receives one dose of Arepanrix
Study NCT01186510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung perfusion
Description: see literature of proceeding
Study NCT01186510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no lung perfusion
Description: see literature of proceeding
Study NCT01002040 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arepanrix
Description: Group B receives 2 doses of Arepanrix 3 weeks apart
Study NCT03344562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES
Description: Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
Study NCT03620240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
Study NCT02113592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary pain program
Description: Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
Study NCT01803204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet - Preoperative Educational
Description: the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
Study NCT03041597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of implants
Description: surgical procedure and placement of implants
Study NCT03041597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: placement of implants
Description: surgical procedure and placement of implants
Study NCT03041597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate loading
Description: cone-anchored implant supported removable dental prostheses placement
Study NCT03041597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional loading
Description: cone-anchored implant supported removable dental prostheses placement in 3mo
Study NCT03041597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankylos implant
Study NCT03041597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankylos implant
Study NCT01118702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin-SR
Description: 3-20mg tablets, once
Study NCT01118702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta
Description: one 54mg tablet, once
Study NCT01118702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo-Methylphenidate ER-C
Description: one 54mg tablet, once
Study NCT04009343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to \<15 kg: 1 tablet, 15 to \<25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
Study NCT04009343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
Study NCT01611649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing dairy lipids and plant oils
Description: 4 months consumption
Study NCT01611649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing plant oils
Description: 4 months consumption
Study NCT01611649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula containing dairy lipids and plant oils, DHA+ARA
Description: 4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
Study NCT00957775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
Study NCT00957775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered ACRA
Description: Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
Study NCT01042587 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: low luminosity red light
Description: Low level red light should not entrain circadian rhythm and will serve as a placebo control
Study NCT00768846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor Resolute Stent
Description: Zotarolimus-eluting Endeavor Resolute Stent
Study NCT02698839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme
Description: Stent platform: cobalt-chromium alloy
Study NCT02698839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BuMA™
Description: Stent platform: stainless steel
Study NCT00935597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)
Description: Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
Study NCT03344562 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CES
Description: Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
Study NCT01287988 — intervention group
Intervention type: DRUG
Intervention: ocriplasmin
Description: Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
Study NCT01287988 — intervention group
Intervention type: DRUG
Intervention: placebo
Description: Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
Study NCT01453686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1%
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
Study NCT01453686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate 0.05%
Description: Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
Study NCT02772835 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medin-cno
Description: Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
Study NCT03905525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Biological
Study NCT03905525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid placebo for injections
Study NCT01153347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet, oral, twice daily for 8 weeks
Study NCT00596336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Description: Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
Study NCT00596336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: trispecific influenza vaccine 0.5 ml subcutaneously
Study NCT00596336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: trispecific influenza vaccine 0.5 ml subcutaneously
Study NCT00768846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V Stent
Description: Everolimus-eluting Xience V Stent
Study NCT01958580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01958580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01958580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo brachytherapy
Study NCT01958580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01958580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT01958580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04296188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plane block
Description: ultrasound guided serratus anterior plane block will be done with % 0.25 bupivacaine.
Study NCT04296188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: ultrasound guided erector spina plane block will be done with % 0.25 bupivacaine.
Study NCT04544982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blue fenugreek kale extract
Description: One capsule to be taken orally before breakfast and one capsule after lunch, with water.
Study NCT01099748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone 50 - 150 mg QD (Day 1)
Study NCT01099748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine + Methadone
Description: Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
Study NCT02019615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
Study NCT02019615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
Study NCT00241410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OralvacB2MPL
Description: Comparison of different dosages of drug
Study NCT01153347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, twice daily for 8 weeks
Study NCT04544982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken orally before breakfast and one capsule after lunch, with water.
Study NCT02834494 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3D Shear Wave Elastography (SWE)
Description: Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
Study NCT00241410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OralvacB2MPL
Description: Comparison of different dosages of drug
Study NCT01127074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KS24.22 cells
Description: The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites.
Study NCT03906123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBP
Description: NBP soft capsules
Study NCT03906123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Soft capsules manufactured to mimic NBP
Study NCT00602225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV
Study NCT00602225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00602225 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously
Study NCT02835820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: 12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
Study NCT03471650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
Study NCT03992716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven® extra Nitrogen
Description: SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
Study NCT03992716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olimel N9E
Description: Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
Study NCT03554746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GC group
Description: 1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps~3. Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~   1. clam ex. without resistance~  2. single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~   <!-- -->~   1. maintain 3rd to 4th ex.~  2. single leg standing on rock board to maintain balance 6th:~   <!-- -->~   1. maintain 5th ex.~  2. lunge ex. without hip internal rotation
Study NCT03554746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CG group
Description: 1. core stability training: hold 5s/rep, 20 reps/times~   1. supine, pelvic posterior tilt with TrA contraction.~  2. supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~  3. All four position with leg raise~2. Stretching ex. : hold 15 s/reps, 5 reps/times~   1. Hamstring~  2. Quadriceps
Study NCT06051019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training: 15 daily sessions (5 sessions per week), each lasting approximately 90 minutes. Sessions will be performed with the assistance or supervision of a physical therapist and will consist of the following steps: 1) warm up with a stationary bike (no load, 10 min, 60 cycles/min); 2) upper and lower limb stretching (10 min); 3) 10 min rest in a sitting position; 4) first exercise bout: stationary bike, 15 min, 60 cycles/min (the load will be modulated so that the participant's heart rate is between 60 and 70% of the estimated maximum heart rate, and the patient perceives moderate fatigue on the Borg Rating of Perceived Exertion; 5) upper and lower limb stretching (10 min); 6) 10 min rest in a sitting position; 7) second exercise bout (same parameters as the first exercise bout); 8) upper and lower limb stretching (10 min).